New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
10:44 EDTECYT, MNKD, BLDP, END, LEAPOptions with increasing implied volatility: ECYT MNKD BLDP END LEAP
News For ECYT;MNKD;BLDP;END;LEAP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
10:02 EDTECYTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:28 EDTECYTEndocyte downgraded to Hold from Buy at Brean Capital
Brean Capital downgraded Endocyte to Hold saying it views the company's data for vintafolide as "marginal."
September 29, 2014
19:32 EDTMNKDMannKind confirms receipt of $150M licensing upfront payment
Subscribe for More Information
18:22 EDTBLDPOn The Fly: After Hours Movers
Subscribe for More Information
17:03 EDTBLDPBallard Power receives ElectraGen fuel cell system order
Subscribe for More Information
06:27 EDTECYTEndocyte to host conference call
Subscribe for More Information
September 28, 2014
14:12 EDTECYTEndocyte says Phase 2b TARGET trial results show improved survival
Endocyte announced that the small molecule drug conjugate, SMDC, vintafolide in combination with docetaxel extended overall survival for patients with folate receptor positive recurrent non-small cell lung cancer, NSCLC, compared to patients receiving monotherapy docetaxel in its TARGET Phase 2b clinical trial. The late-breaking TARGET trial data will be presented today at the European Society for Medical Oncology Congress, ESMO, by Rohit Lal, M.D., consultant medical oncologist at Guys and St Thomas' Hospital and an Honorary Consultant Medical Oncologist for Kings College Hospital, London.
September 24, 2014
17:01 EDTMNKDMannKind announces closing of global licensing agreement with Sanofi
Subscribe for More Information
September 18, 2014
07:55 EDTENDEndeavour receives notice of non-compliance with NYSE listing standards
Endeavour has been notified by the NYSE that it is not in compliance with two of the NYSE's continued listing standards. The NYSE requires that the average closing price per share of a listed company's stock be in excess of $1.00 for a consecutive 30-trading day period. Under this continued listing criteria, Endeavour has a period of six months, subject to possible extension, to bring its average share price back over $1.00. The company's common stock expects to be listed and traded on the NYSE during this period. In addition, the company's total market capitalization has averaged less than $50M over a consecutive 30 trading-day period and its last reported shareholders' equity was also below $50M. Endeavour has 45-days from receipt of the NYSE notice to submit a business plan to the NYSE demonstrating how it intends to comply with the NYSE's continued listing standards. The company's stock expects to trade on the NYSE during the plan period.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use